Here are three things to know:
1. Patients will undergo a one- or two-level XLIF procedure with smooth PEEK, Modulus 3D-printed titanium or Cohere Porous PEEK implants.
2. The study will also generate level 1 biologic outcome evidence, as each implant group will have randomization between Osteocel Pro and cancellous allograft chips with bone marrow aspirate
3. In this two-year, follow-up study, at least 10 surgeons will assess the fusion progression in approximately 300 U.S. patients.
More articles on surface technology:
Nexxt Spine starts 1st trial of 3D-printed lumbar interbody fusion device vs. PEEK: 4 notes
Captiva Spine earns FDA clearance for 3D-printed titanium cervical cages: 3 insights
CoreLink launches expandable interbody fusion device: 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.